Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

(2020) Alexander Drilon et al.   NATURE MEDICINE

Diagnosis of fusion genes using targeted RNA sequencing

(2019) Erin E. Heyer et al.   Nature Communications

High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden

(2019) Ryma Benayed et al.   CLINICAL CANCER RESEARCH

An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer

(2019) Brian C. Haynes et al.   Translational Oncology

Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors

(2019) Carina Heydt et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays

(2019) Nicole Pfarr et al.   GENES CHROMOSOMES & CANCER

Targeted RNA‐sequencing assays: a step forward compared to FISH and IHC techniques?

(2019) Gaëlle Tachon et al.   Cancer Medicine

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer

(2018) Petros Christopoulos et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Crizotinib among Different Types of  ROS1 Fusion Partners in Patients with ROS1 -Rearranged Non–Small Cell Lung Cancer

(2018) Ziming Li et al.   Journal of Thoracic Oncology

Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples

(2018) Kurtis D. Davies et al.   Journal of Thoracic Oncology

EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report

(2018) You-cai Zhu et al.   LUNG CANCER

Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples

(2018) Stine H. Kresse et al.   PLoS One

ALK- rearrangement in non-small-cell lung cancer (NSCLC)

(2018) Xue Du et al.   Thoracic Cancer

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

(2016) K. Konduri et al.   Cancer Discovery

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

(2015) Nicole Pfarr et al.   GENES CHROMOSOMES & CANCER

The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy

(2015) Jeffrey S. Ross et al.   INTERNATIONAL JOURNAL OF CANCER

Genomic alterations in lung adenocarcinoma

(2015) Siddhartha Devarakonda et al.   LANCET ONCOLOGY

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer

(2014) R. Wang et al.   CLINICAL CANCER RESEARCH

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials

(2013) William D. Travis et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

(2013) Sarah Walters et al.   THORAX

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer

(2012) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

(2011) L. V. Sequist et al.   ANNALS OF ONCOLOGY

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

(2011) Y. S. Ju et al.   GENOME RESEARCH

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

(2011) Chenguang Li et al.   PLoS One

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER